chronic hepatitis B and C
Infectious disease · 2017–2017
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| peginterferon alfa-2a Chronic hepatitis B and C infection, with potential off-label use in myeloproliferative neoplasms (MPN) including essential thrombocythemia and polycythemia… | Nov 2017 | Recommended with restriction | 4 individuals Rare Cancers Australia |
Who spoke
Rare Cancers Australia
What the PBS pays
$11M in government benefit over 2024–25, across 19,965 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| peginterferon alfa-2a | $11M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.